Home/Filings/4/0001395064-22-000146
4//SEC Filing

TAKEDA PHARMACEUTICAL CO LTD 4

Accession 0001395064-22-000146

$TAKCIK 0001888012other

Filed

Nov 30, 7:00 PM ET

Accepted

Dec 1, 5:47 PM ET

Size

9.5 KB

Accession

0001395064-22-000146

Insider Transaction Report

Form 4
Period: 2022-11-30
Transactions
  • Exercise of In-Money

    Warrant (Right to Buy)

    2022-11-305,883,5000 total(indirect: See Explanation of Responses)
    Exercise: $0.00From: 2022-05-03Exp: 2031-07-02Common Stock (5,883,500 underlying)
  • Exercise of In-Money

    Common Stock

    2022-11-30+5,883,5006,724,000 total(indirect: See Explanation of Responses)
Transactions
  • Exercise of In-Money

    Common Stock

    2022-11-30+5,883,5006,724,000 total(indirect: See Explanation of Responses)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2022-11-305,883,5000 total(indirect: See Explanation of Responses)
    Exercise: $0.00From: 2022-05-03Exp: 2031-07-02Common Stock (5,883,500 underlying)
Footnotes (2)
  • [F1]On November 30,2022, the Reporting Person exercised a Warrant to purchase 5,883,500 shares of the Issuers common stock with an exercise price of $0.0000595 per share.
  • [F2]Takeda Pharmaceutical Company Limited has beneficial ownership of the reported securities, all of which are held directly by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of TakedaPharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) andTakeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Issuer

HilleVax, Inc.

CIK 0001888012

Entity typeother

Related Parties

1
  • filerCIK 0001395064

Filing Metadata

Form type
4
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 5:47 PM ET
Size
9.5 KB